Cargando…

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

OBJECTIVE: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svenningsson, Anders, Bergman, Joakim, Dring, Ann, Vågberg, Mattias, Birgander, Richard, Lindqvist, Thomas, Gilthorpe, Jonathan, Bergenheim, Tommy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345631/ https://www.ncbi.nlm.nih.gov/pubmed/25745637 http://dx.doi.org/10.1212/NXI.0000000000000079

Ejemplares similares

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
por: Bergman, Joakim, et al.
Publicado: (2020)

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction
por: Vågberg, Mattias, et al.
Publicado: (2015)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
por: Bergman, Joakim, et al.
Publicado: (2020)

Brain Parenchymal Fraction in Healthy Adults—A Systematic Review of the Literature
por: Vågberg, Mattias, et al.
Publicado: (2017)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
por: Al Nimer, Faiez, et al.
Publicado: (2016)

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
por: de Flon, Pierre, et al.
Publicado: (2018)

B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
por: Pescovitz, Mark D., et al.
Publicado: (2014)

PATIENTS’ EXPECTATIONS BEFORE INITIATION OF INTRATHECAL BACLOFEN TREATMENT: A LONGITUDINAL STUDY WITH 1-YEAR FOLLOW-UP
por: GUNNARSSON, STINA, et al.
Publicado: (2023)

Acute painful lumbosacral paresthesia after intrathecal rituximab
por: Bromberg, J. E. C., et al.
Publicado: (2011)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
por: Tjensvoll, Anne Bolette, et al.
Publicado: (2019)

Neuropsychological Function and Quality of Life after Resection of Suspected Lower-Grade Glioma in the Face Primary Motor Area
por: Stålnacke, Mattias, et al.
Publicado: (2021)

Rituximab: B cell depletion: case report
Publicado: (2021)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
por: Khademi, Mohsen, et al.
Publicado: (2013)

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
por: Bonnan, Mickael, et al.
Publicado: (2021)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab
por: Linden, Johan, et al.
Publicado: (2019)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
por: Gauthier, Martin, et al.
Publicado: (2019)

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
por: Vågberg, M., et al.
Publicado: (2016)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

B Cell Depletion: Rituximab in Glomerular Disease and Transplantation
por: Marinaki, S., et al.
Publicado: (2013)

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?
por: Damianaki, Anthie, et al.
Publicado: (2022)

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment
por: Fluge, Øystein, et al.
Publicado: (2015)

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity
por: Lehmann-Horn, Klaus, et al.
Publicado: (2014)

Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors
por: Horiuchi, Makoto, et al.
Publicado: (2022)

Intravenous immunoglobulin prevents peripheral liver transduction of intrathecally delivered AAV vectors
por: Horiuchi, Makoto, et al.
Publicado: (2022)

The spectrum of use of rituximab in chronic lymphocytic leukemia
por: Tedeschi, Alessandra, et al.
Publicado: (2010)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
por: Gentile, M, et al.
Publicado: (2010)

Convalescent-anti-sars-cov-2-plasma/dexamethasone/rituximab: Depletion of B-lymphocytes, lack of efficacy and off label treatment: case report
Publicado: (2022)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report
por: Balaban, Denis T., et al.
Publicado: (2023)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue
por: Joly-Battaglini, Albane, et al.
Publicado: (2016)

Pathology of rituximab-induced Kaposi sarcoma flare: role of B-cell depletion
por: Pantanowitz, L, et al.
Publicado: (2009)

Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis
por: Krishnan, Parameswaran, et al.
Publicado: (2022)

Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions
por: Alaibac, Mauro
Publicado: (2018)

B lymphocyte-typing for prediction of clinical response to rituximab
por: Brezinschek, Hans-Peter, et al.
Publicado: (2012)

B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis
por: van Laar, Jacob M
Publicado: (2010)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_c4esk8mv3kc587v52u6otjh3hk